Understanding how genetics and clinical factors affect treatment response in Crohn's disease
Precision Medicine in Inflammatory Bowel Disease: Refining the Clinical and Genomic Predictors of Response to Anti-IL-12/23 Therapy
This study is looking at how your genes and health details can help doctors figure out if anti-IL-12/23 therapy will work well for you if you have Crohn's disease, so they can choose the best treatment for you.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11018564 on NIH RePORTER |
What this research studies
This research investigates how genetic and clinical characteristics influence the effectiveness of anti-IL-12/23 therapy in patients with Crohn's disease. By analyzing patient data and utilizing machine learning techniques, the study aims to identify specific patterns that predict which patients are more likely to benefit from this treatment. The goal is to refine treatment strategies and improve the selection of first-line therapies for Crohn's disease, ultimately enhancing patient outcomes. Participants may undergo assessments that include genetic testing and clinical evaluations to gather relevant data.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Crohn's disease who are considering or currently receiving anti-IL-12/23 therapy.
Not a fit: Patients with Crohn's disease who are not candidates for anti-IL-12/23 therapy or those with other gastrointestinal conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for patients with Crohn's disease.
How similar studies have performed: Previous research has shown promise in using genetic and clinical data to predict treatment responses in autoimmune diseases, suggesting that this approach may yield valuable insights.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Cushing-Damm, Kelly Colleen — University of Michigan at Ann Arbor
- Study coordinator: Cushing-Damm, Kelly Colleen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.